Skip to content
Home/Companies/Biotech/Axelar

Axelar

Biotech·Sweden·Active·13yr hold
Entry
2013
Hold
13yr
Status
Active

Who owns Axelar?

Axelar is currently owned by Rosetta Capital through Rosetta Capital IV (2013 vintage), since 2013.

Hand-verified · updated 2026-06-30

Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorBiotech
StatusActive

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Akinion Pharmaceuticals
Active
PharmaSweden· 2013
Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Dilafor
Active
BiotechSweden· 2013
Inhalation Sciences
Inhalation Sciences
Active
MedTechSweden· 2013

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Axelar

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Axelar?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Axelar.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue